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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
low-level laser therapy is an effective treatment for patients with primary Raynaud’s 
Phenomenon.  
STUDY DESIGN: Review of three randomized, double blind, placebo controlled trials, 
published between 2002-2004.  
DATA SOURCES: Randomized, double blind clinical trials comparing low-level laser 
therapy with a placebo treatment were found using the Cochrane databases, and PubMed. 
 OUTCOME MEASURED: Reduction in frequency and severity of Raynaud’s attacks. 
Outcomes were measured and recorded with daily diaries of attacks before and after the 
intervention, and thermographic studies.  
RESULTS: Three RCTs were included in this review. The RCT by Hirschl et al. 2002, 
showed a decrease in frequency of attacks from 0.86 to 0.67 with the laser therapy, which 
was more than with the sham treatment, but not statistically significant. It was, however, 
significant in lowering the intensity of attacks. The RCT by Hirschl et al. 2004 showed 
that both the number of attacks and their intensity were significantly reduced during the 
period of laser therapy compared to the sham treatment. Intensity of attacks was reduced 
82% with laser therapy. The RCT by Al-Awami et al. 2004, also showed a statistically 
significant improvement in both frequency and intensity of attacks.  
CONCLUSIONS: All three RCTs showed that low level laser therapy decreased the 
frequency or intensity of Raynaud’s attacks more effectively than when exposed to a 
sham treatment, and it seems to be an option for treating these attacks. Further studies 
should be conducted to understand the pathogenetic mechanism of LLLT on Raynaud’s 
phenomenon and it’s place in treatment.  
Key Words:  primary Raynaud’s phenomenon; low-level laser therapy 
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INTRODUCTION 
 Raynaud’s is a disorder in which small blood vessels of the extremities have reduced 
blood flow when they are exposed to cold, or emotional distress. Under these conditions, the 
blood vessels go into spasms, causing pain, numbness, throbbing or tingling. Typically, the 
fingers are most commonly affected, changing from white and even blue within minutes of 
exposure, and then becoming red after being warmed. Primary Raynaud’s is not linked to an 
underlying medical condition, whereas secondary Raynaud’s is associated with another condition 
or disease, usually rheumatic in nature.1 Although Raynaud’s phenomenon is often self-limiting, 
vasodilator drugs have been used in severe cases where it interferes with the person’s life. 
However, these drugs many times have restrictions; such as lack of consistency, tolerance 
development and side effects that may become intolerable for the patients.2 This paper evaluates 
three randomized controlled trials (RCTs) comparing the efficacy of low-lever laser therapy 
(LLLT) with no treatment, with the ultimate goal of reduction in frequency and intensity of 
Raynaud’s attacks. 
 Raynaud’s attacks affect up to 10% of the adult population, hence making it relevant to 
all healthcare providers, including physician assistants in practice. It tends to target females more 
than males.2 During a Raynaud’s attack, the pallor of the digits, that cause cyanosis, pain and 
numbness, lead to a decreased quality of life, and restrict patients from performing certain 
activities or occupations.2,3 The cost of this condition has not been determined due to the fact that 
only 1 in 5 people with this condition are aware that it is medically related and actively seek 
treatment.1 The condition may be mild and not affecting their daily lives, and they may simply 
attribute it to having poor circulation or being sensitive to cold climates.1 Many will often 
present to a primary care doctor and be referred to a rheumatologist.1 
Ruiz: Low-Level Laser Therapy and Primary Raynaud’s Phenomenon 2   
 Primary Raynaud’s phenomenon is often a benign disease, but it often reduces a patient’s 
quality of life. The underlying pathogenic process in Raynaud’s phenomenon is unclear.2 Studies 
suggest the possibility of endothelial dysfunction. It has been shown that there are increased 
levels of endothelial function and platelet activation, including the release of endothelin and von-
Willebrand factor. These factors reduce the endothelial release of nitric oxide, leading to the 
proposition that Raynaud’s phenomenon could have to do with endothelial-dependent 
vasoregulation.2  
 Current methods used to treat this condition include self-limiting treatment, which is 
simply keeping warm, and putting extremities under warm water2. However, this is not treatment 
enough for many people. Biofeedback has also been tried with limited results.4 Vasodilator drugs 
have been used with some success, including calcium channel blockers and α- adrenergic 
blockers. However, most of these drugs have side effects or limitations, including lack of 
consistency, development of tolerance, development of side effects including dizziness, 
headaches, palpitations, and orthostatic hypotension.2 For this reason, low-level laser treatment is 
being proposed. The use of low-level laser therapy has been shown to improve patient’s 
complaints in frequency and severity or attacks compared to placebo treatment without the side 
effects.2 
OBJECTIVE 
  The objective of this selected EBM review is to determine whether or not low-level laser 
therapy is an effective treatment for patients with primary Raynaud’s phenomenon.  
METHODS 
 Criteria for selection of studies included patients with primary Raynaud’s 
phenomenon. The intervention used was low-level laser therapy, and was compared with no 
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treatment, which in this case was a sham laser. The outcomes measured in these studies were the 
reduction in frequency and severity of Raynaud’s attacks in patients with primary RP. The 
studies included in this EBM review include 3 RCTs comparing LLLT with no treatment.  
 Key words used in searches included: primary Raynaud’s phenomenon and low-level 
laser therapy. Two articles were first published in German: M. Hirschl et al. Double-blind, 
randomized, placebo controlled low level laser therapy study; and M. Al-Alwami et al, Low 
Level laser therapy for treatment of RP. One article was published in English: Hirschl et al: 
Laser therapy in RP. All articles were published in peer-reviewed journals. Literature searches 
occurred via Cochrane databases and PubMed. Articles were selected based on importance of 
outcomes to the patient (POEMS). Inclusion criteria included patients with primary Raynaud’s 
phenomenon (RP). The diagnosis of primary RP was established by the exclusion of associated 
disease or known cause for RP. Patients under the age of 18 were excluded, those over the age of 
65, and those women of childbearing age not using adequate contraception. Also, patients could 
not be using any vasoactive medication. Summary of statistics reported or used were p-values, 
Wilcoxon paired test, ANOVA, Chi-square, Bartlett test, and the Kolmogorov-Smirnov test. 
Table 1 demonstrates the demographics included in the studies.  
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Table 1: Demographics and characteristics of included studies 
 
Study Type # 
Pts 
Age 
yrs 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
M. Al-
Awam
i, 2004 
2 
RCT 47 18-
65 
Patients with RP for 
2 yrs or more and at 
least 4 episodes of 
RP per week. 
Established dx of 
RP, by exclusion of 
associated diseases 
that cause 
secondary RP.  
Any patients 
taking 
vasodilator 
drugs. Patients 
under the age of 
18, over the age 
of 65, and 
women of 
childbearing age 
not using 
adequate 
contraception. 
0 10 sessions of low 
level laser distant 
irradiation 
treatment. 
Exposure time: 
1000 sec per 
session, intensity: 
400 mW, power 
density 2.2 mW 
per square cm 
applied to palms 
and fingers of 
both hands 
simultaneously 
M. 
Hirsch
l, 2002 
3 
RCT 15 36-
70 
Patients with 
established primary 
RP 
Patients must be 
part of a long-
term study, 
selected during 
the cold season 
of Dec. 2000- 
March 2001, in 
which diagnostic 
procedures for 
detection of 
underlying 
diseases and 
follow-up 
control 
established, for 
exclusion of 
secondary RP 
Patients could 
not use 
vasoactive 
medications 
3 3-week period of 
diode array (low 
level laser 200 
mW, wavelength 
625 nm) for 30-40 
min, 5 times per 
week.  
Hirsch
l, 2004 
4 
RCT 48 32-
60 
Patients diagnosed 
with primary RP 
according to 
diagnostic clinical 
criteria. Patients 
unassociated with 
other diseases. 
Patients taking 
vasoactive 
medication that 
could interfere 
with vascular 
response  
2 3 week period of 
diode laser 
(power 200 mW, 
wavelengths 685 
nm) for 30-40 
min, 5 times per 
week 
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OUTCOMES MEASURED 
 The outcomes measured included the reduction in frequency and severity of Raynaud’s 
attacks. The outcomes were measured in all the studies with recorded daily diaries of attacks 
before and after the intervention. Thermographic studies were also performed before in the study 
by Al-Alwami.  The thermographic study was done before the start of the trial and 6 weeks after 
the irradiation. A standardized cold-warm challenge test using computerized thermography of 
continuous temperature recordings was performed. The basal finger-tip skin temperatures was 
performed after being in room temperature for 20 min; after 1 min. warm challenge (immersion 
of gloved hand in water at 39° C), and after 1 min. cold challenge (immersion of gloved hand in 
water at 20° C).  
RESULTS 
The three randomized controlled trials in this review were all presented in continuous 
data. None of the data was dichotomous and could not be converted to dichotomous data.  
 Al. Alwami et al. 2004, presented all continuous data, used Chi-square to compare 
proportions, and considered p-value < 0.05 as statistically significant. Paired continuous 
variables were compared by Wilcoxon paired test. Overall, the frequency and severity of patients 
with RP was reduced with LLLT (frequency p < 0.0001, severity p  < 0.0001), better than with 
placebo (frequency p < 0.0001, severity p  < 0.02). In addition, there was a significant 
improvement in frequency and severity at 6 weeks (frequency p = 0.007, severity p = 0.02) and 3 
months (frequency p = 0.02, severity p = 0.04), as shown in Table 2.  
 
 
Table 2: Comparison of the frequency and severity of RP attacks before and after LLLT 
and placebo treatment (tx) 
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 LLLT group (n = 
24) 
Placebo group (n= 23) P-value 
Baseline    
Frequency of RP 7 7 0.8 
Severity of RP 6 5 0.5 
6 weeks after tx    
Frequency of RP 3 5 0.007 
Severity of RP 1 4 0.02 
3 months after tx    
Frequency of RP 3 6 0.02 
Severity of RP 0 4 0.04 
P-value    
Frequency of RP < 0.0001 <0.0001  
Severity of RP < 0.0001 0.02  
 
Improvement in thermographic response to cold challenge was only seen in patients 
treated with LLLT and not seen in patients treated with placebo, as can be seen in Table 3. There 
were no adverse effects or safety concerns in patients treated with LLLT.  
Table 3: Temperatures of patients measured during cold challenge test, before and 6 
weeks after LLLT and placebo 
 LLLT group (n = 24) C° Placebo group (n = 23) C° 
Cold challenge test- baseline   
Temperature difference after 
20 min recovery 
-2.3 ° -2.5 ° 
Cold challenge test – 6 weeks    
Temperature difference after 
20 min recovery 
-0.6 ° -1.0 ° 
P-value 0.02 0.1 
 
 Hirschl et al. 2002, presents the frequency and severity of attacks statistically by using 
the Bartlett’s tests and the Kolmogorov-Smirnov test. For all statistical comparisons, a p-value 
less than 0.05 was considered significant. Table 4 shows frequency of attacks of Raynaud’s 
attacks during the 3 weeks of LLLT or placebo. Relative frequency of RP attacks was reduced 
from 0.86 in week 1, to 0.67 in week 3 of LLLT, compared to the placebo with 0.90 in week 1 to 
0.72 in week 3.  
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Table 4: Relative frequency of attacks during the 3 weeks of LLLT or placebo therapy 
 Week 1  Week 2  Week 3 
Laser  0.86 +/- 0.93 0.69 +/- 0.46 0.67 +/- 0.42 
Placebo 0.90 +/- 0.83  0.86 +/- 0.67 0.72 +/- 0.32 
 
Even though the frequency of attacks did decrease with LLLT, it was not statistically 
significant (p = 0.520). Table 5 shows the average intensity for each week, which did decrease 
significantly. In spite of this, there was no residual effect of LLLT after the third week, when no 
treatment was implemented; hence the effects of the laser therapy may only be of short duration.  
Table 5: Mean Intensity of symptoms measured on a 5-point scale before treatment 
and at end of weeks 1 -3 of laser and placebo therapy 
 Pre-Treatment Week 1 Week 2 Week 3  
Laser  3.3 2.5 2.5 2.6 
Placebo 3.3 3.0 3.0 3.2 
 
 Hirschl et al. 2004, uses ANOVA to compare laser and placebo conditions, 
controlling for sequence of conditions to assess for potential differences across experimental 
conditions. Normality was assessed by the Kolmogorov-Smirnov tests. Ambient temperature was 
statistically not different between sham and laser exposure (sham 3.2 +/- 3.6 C°; laser 3.0 +/- 3.9 
C°). Table 6 shows the frequency and the severity of attacks were significantly reduced during 
the LLLT compared to the sham treatment. Intensity of attacks was reduced with placebo was 
only slightly reduced (96% of pre-treatment intensity), compared to the results with the laser 
therapy (82% of pre-treatment intensity). Table 6 also shows that exposure or evoking conditions 
(cold, wetness, etc.) did not differ between pre-treatment phase and laser and place therapy 
phase, which where each 3 weeks. Although all measures were favorable for LLLT, none of 
them reached statistical significance, as shown by Table 6.  
Table 6: Mean of average number of exposures per day, attacks per day, intensity of 
attacks (5-point scale, minimal to severe; absolute and relative to week preceding 
treatment) for each week of laser and placebo treatment 
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   Laser   Placebo   
 Pre 1st 2nd 3rd 1st 2nd 3rd P 
Exposure 3.0 3.0 2.9 2.9 2.9 3.0 2.9  0.881 
Attacks 2.5 1.8 1.6 1.6 2.1 2.2 2.0 0.001 
Attacks 
relative to 
exposure 
90 72 66 66 83 82 78 0.008 
Intensity 3.2 2.5 2.3 2.3 2.9  2.8 2.8 < 0.001 
Intensity 
relative to 
pre-
treatment 
 87 80 78 96 96 94 < 0.001 
 
DISCUSSION  
The study by Al-Awami was a double-blind placebo controlled trial, which showed that 
LLLT resulted in more significant improvement in the symptoms of Raynaud’s attacks, when 
compared with the placebo treatment. Even though there was an improvement in frequency and 
severity in RP attacks, there was also some improvement with the placebo treatment. This shows 
possible psychological influence. However, LLLT had a more significant improvement of patient 
complaints. There was also a thermographic improvement that the placebo treatment did not 
have. In terms of demographics, the diversity among patients with RP is a weakness in the trial, 
with patients ranging from 18-65 years old. There were no noted side effects during the trial with 
LLLT, making the efficacy of this laser treatment more appealing in the treatment of primary 
RP.  
 The study by Hirschl et al. 2002, demonstrates that ultimately the frequency of attacks is 
only slightly influenced by LLLT, and not statistically significant. However, severity of attacks 
is statistically significantly reduced. Despite the randomized crossover design of the trial, the 
psychological effect of patient expectations must be considered. Unfortunately, the slightly 
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positive effects of LLLT are only in short duration, and there was no transfer effect from laser to 
sham condition.  
 Finally the study by Hirschl et al. 2004, also using a crossover design, using each subject 
as their own control, showed that frequency and intensity of attacks was reduced by a clinically 
significant amount. The study demonstrated that patients with cold as the only trigger, and 
patients that have a more pronounced temperature decrease, showed a better response to LLLT. 
This may suggest an intrinsic heterogeneity of the clinical presentation of primary RP, and 
differential therapeutic effects based on the differing intensity of vasospasms after cold 
provocation.  This could possibly be due to endothelium- independent factors, a current theory of 
the pathogenesis of RP that must be further studied. Even though there was a beneficial effect 
with placebo, the effects failed to reach statistical significance, while those treated with LLLT 
had a substantial therapeutic effect in this trial. Although LLLT seems promising, there may not 
be much more than scientific interest to overcome the shortage of available resources that would 
make this treatment clinically effective.  
CONCLUSION 
 Based on the studies reviewed, low-level laser therapy appears to be an effective 
treatment in treating patients with primary Raynaud’s phenomenon. Even though there were 
some improvements seen in the placebo groups as well, attributing some of the improvements to 
psychological effect, those subjects treated with LLLT had a more significant therapeutic effect 
in all of the trials. In addition, none of the studies showed side effects or undesirable outcomes, 
demonstrating that LLLT is a safe and effective alternative to the current treatments for those 
with primary Raynaud’s phenomenon. The trials, however, showed the effects of LLLT to be of 
short-term benefit, and not necessarily a permanent or long duration treatment.  
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 The underlying mechanism of action of LLLT is still unknown, and further studies should 
be implemented to determine this mechanism, whether it is due to endothelium-independent 
factors or not. Also providing more insight into the mechanism of action of LLLT may help in 
promoting endurance in the effects of this therapy. More knowledge in this area may help make 
this treatment one that is more desirable and help overcome the possible shortage of available 
resources that forms a barrier to making this an efficient and effective treatment for those 
patients with primary Raynaud’s phenomenon.  
 REFERENCES 
 
 
1. Frequently Asked Questions. Raynaud’s Association. 
http://www.raynauds.org/index.php/raynauds/frequently-asked-questions/. Accessed Oct. 
1, 2011.  
 
2. Al- Awami M, Schillinger M, Maca T, Pollanz S, Minar E. Low level laser therapy for 
treatment of primary and secondary Raynaud’s phenomenon. Vasa. 2004; 33 (1): 25-29. 
 
3. Hirschl M, Katzenschlager R, Ammer K, Meinizki P, Rathkolb O, Kundi M. Double- 
blind, randomized, placebo controlled low level laser therapy study in patients with 
primary Raynaud’s phenomenon. Vasa. 2002; 31 (2): 91-94. 
 
4. Hirschl M, Katzenschlager R, Francesconi C, Kundi M. Low level laser therapy in 
primary Raynaud’s phenomenon- results of a placebo controlled, double blind 
intervention study. J. Rheumatol. 2004; 31 (12): 2408-2412.  
 
 
 
 
